Pacific Biosciences of California, Inc. (PACB) has a negative trailing P/E of -0.8, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -128.35%.
Criteria proven by this page:
Overall SharesGrow Score: 41/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -4.6 | -0.05 | 4.00 | 3.73 | - |
| 2017 | -3.0 | -0.63 | 3.24 | 2.98 | - |
| 2018 | -9.7 | 0.77 | 8.76 | 12.70 | - |
| 2019 | -9.3 | 0.28 | 14.28 | 8.63 | - |
| 2020 | 145.7 | -1.08 | 12.77 | 54.31 | - |
| 2021 | -23.0 | 0.04 | 5.27 | 31.92 | - |
| 2022 | -5.8 | -0.10 | 3.26 | 14.32 | - |
| 2023 | -8.1 | 0.60 | 3.55 | 12.41 | - |
| 2024 | -1.6 | 0.25 | 0.99 | 3.26 | - |
| 2025 | -1.0 | -0.02 | 104.87 | 3.51 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-0.83 | $90.71M | $-74.38M | -82% |
| 2017 | $-0.87 | $93.47M | $-92.19M | -98.6% |
| 2018 | $-0.76 | $78.63M | $-102.56M | -130.4% |
| 2019 | $-0.51 | $90.89M | $-77.82M | -85.6% |
| 2020 | $0.17 | $78.89M | $29.4M | 37.3% |
| 2021 | $-0.89 | $130.51M | $-181.22M | -138.9% |
| 2022 | $-1.40 | $128.3M | $-314.25M | -244.9% |
| 2023 | $-1.21 | $200.52M | $-306.74M | -153% |
| 2024 | $-1.07 | $154.01M | $-309.85M | -201.2% |
| 2025 | $-1.82 | $160.01M | $-546.38M | -341.5% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.52 | $-0.52 – $-0.51 | $174.28M | $172.4M – $175.58M | 4 |
| 2027 | $-0.48 | $-0.48 – $-0.47 | $196.75M | $196.7M – $196.8M | 4 |
| 2028 | $-0.42 | $-0.45 – $-0.34 | $223.76M | $222.7M – $224.82M | 6 |
| 2029 | $-0.35 | $-0.35 – $-0.35 | $243.33M | $240.7M – $245.15M | 4 |
| 2030 | $-0.31 | $-0.32 – $-0.31 | $269.93M | $267.01M – $271.95M | 2 |
